证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0034 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 信达澳银基金管理有限公司 睿扬投资 罗会 ...

Revenue and Profit - Revenue for Q3 2022 reached ¥383,482,150.04, an increase of 17.08% year-over-year, while total revenue for the year-to-date was ¥1,175,028,595.83, up 21.26% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥38,794,132.60, a significant increase of 71.48% year-over-year, with year-to-date net profit at ¥168,876,231.79, up 31.52%[7] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥35,717,425.87, a remarkable increase of 457.91% year-over-year, while year-to-date figures showed an increase of 67.38% to ¥156,080,799.46[7] - Basic and diluted earnings per share for Q3 2022 were both ¥0.0476, reflecting a 71.22% increase compared to the same period last year[7] - Total operating revenue for the current period reached ¥1,175,028,595.83, an increase of 21.3% compared to ¥969,008,945.04 in the previous period[27] - Net profit for the current period was ¥189,378,012.57, representing a 55.8% increase from ¥121,591,358.11 in the previous period[30] - Earnings per share (EPS) for the current period was ¥0.2074, compared to ¥0.1577 in the previous period, reflecting a 31.5% increase[32] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥3,193,165,938.79, a slight decrease of 0.15% from the end of the previous year, while equity attributable to shareholders increased by 5.54% to ¥2,359,745,363.70[7] - The total liabilities are reported at ¥466,968,535.87, compared to ¥603,237,286.18 previously[23] - The company's total liabilities decreased to ¥492,014,940.07 from ¥628,539,798.06, indicating a reduction of approximately 21.7%[26] - Total equity attributable to shareholders increased to ¥2,359,745,363.70 from ¥2,235,838,542.50, marking a growth of 5.5%[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥247,371,958.46, representing an increase of 8.27% compared to the same period last year[7] - Cash inflow from operating activities totaled ¥1,210,617,750.13, an increase from ¥1,060,825,645.53 in the previous period[33] - The net cash flow from operating activities was $247,371,958.46, an increase from $228,477,820.16 in the previous period, reflecting a growth of approximately 4%[35] - Total cash inflow from investment activities reached $514,188,001.96, significantly higher than $241,445,648.28 in the prior period, marking an increase of about 113%[35] - The company reported a significant increase in cash received from investment recoveries, totaling $507,142,234.96, compared to $179,576,646.56 in the previous period, indicating a growth of approximately 182%[35] Expenses and Investments - The company reported a significant decrease in financial expenses, which were -¥14,093,562.17 for the year-to-date, a reduction of 1899.88% year-over-year due to increased deposit income and reduced bank loan interest payments[12] - Research and development expenses for the current period were ¥47,557,128.54, down from ¥53,347,000.10 in the previous period, a decrease of 10.8%[27] - The company has a long-term investment in equity amounting to ¥17,402,050.83, down from ¥19,093,016.10[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 152,377[16] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[16] Inventory and Receivables - Accounts receivable increased to ¥275,852,312.81 from ¥213,685,445.94, reflecting a growth of approximately 29%[20] - Inventory as of September 30, 2022, is valued at ¥332,331,582.47, up from ¥323,123,183.77[23]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 791,546,445.79, representing a 23.39% increase compared to CNY 641,476,445.23 in the same period last year[28]. - The net profit attributable to shareholders for the same period was CNY 130,082,099.19, up by 22.98% from CNY 105,777,610.05 year-on-year[28]. - The net profit after deducting non-recurring gains and losses was CNY 120,363,373.59, reflecting a 16.60% increase from CNY 103,228,338.93 in the previous year[28]. - The basic earnings per share increased to CNY 0.1598, a rise of 23.02% compared to CNY 0.1299 in the same period last year[28]. - The company achieved consolidated sales revenue of CNY 791.55 million, a year-on-year increase of 23.39%[48]. - The net profit attributable to the parent company was CNY 130 million, reflecting a year-on-year growth of 22.98%[48]. - Operating cash flow was CNY 142.55 million, down 22.55% compared to the previous year[54]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,133,982,972.17, a decrease of 2.00% from CNY 3,198,096,241.82 at the end of the previous year[28]. - The net assets attributable to shareholders increased by 3.72% to CNY 2,319,053,070.76 from CNY 2,235,838,542.50 at the end of the previous year[28]. - Cash and cash equivalents decreased to ¥558,970,624.74, accounting for 17.84% of total assets, down from 20.37% last year[61]. - Accounts receivable increased to ¥280,132,631.50, representing 8.94% of total assets, up from 6.68% last year[61]. - Inventory increased to ¥345,390,156.01, accounting for 11.02% of total assets, compared to 10.10% last year[61]. Operational Highlights - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, chemical raw materials, and biopharmaceuticals[37]. - Key products include Wang's Baocuo Pills, which are used for various pediatric and adult digestive issues, and Jide Sheng Snake Medicine Tablets, known for their detoxifying and anti-inflammatory properties[38]. - The production of methyl hydrazine at Nantong Dongli increased by 80.97% year-on-year[50]. - The company launched new products in the chlorine and fluorine series, maintaining stable market share for certain products[50]. - The company applied for 12 patents during the reporting period, indicating a focus on innovation[54]. Quality Control and Certifications - The company has implemented strict quality control measures in production, adhering to GMP standards to ensure product safety and quality[42]. - The company received European COS certification for five products, and FDA on-site audits were passed for others, indicating strong quality control capabilities[47]. - The company has obtained GMP certification for its subsidiaries and some products have passed FDA and COS certifications, ensuring drug quality safety[124]. Environmental Management - The company reported a total COD emission of 16.7296 tons, well below the approved limit of 117.115 tons per year, indicating compliance with environmental standards[97]. - The ammonia nitrogen emissions were recorded at 0.3414 tons, significantly lower than the annual limit of 10.362 tons[97]. - The company has established a wastewater treatment facility with a daily capacity of 1000 tons, ensuring effective management of wastewater[100]. - The company has invested in air pollution control facilities, including a waste gas incineration system with capacities of 30,000 m³/h and 50,000 m³/h[100]. - The company has implemented a comprehensive waste management system, with no direct discharge of industrial wastewater and solid waste being properly collected and disposed of[103]. Risk Management - The management has highlighted potential risks related to raw material procurement, sales price declines, product quality, and environmental safety[5]. - The company faces risks related to industry policies, including increased regulatory scrutiny and potential impacts on future development due to government pricing adjustments[78]. - Raw material procurement risks are highlighted, particularly due to the volatility in prices and supply shortages of traditional Chinese medicine materials, which could adversely affect profitability[79]. - The company has invested significantly in drug research and development, but faces risks related to increased funding requirements and potential delays in drug registration processes[80]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, indicating a focus on reinvestment[92]. - The company has maintained a stable governance structure, with no changes in its board of directors or senior management during the reporting period[91]. - The total number of ordinary shareholders at the end of the reporting period is 167,182[178]. - The largest shareholder, Nantong Industrial Holding Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares, with a decrease of 6,597,500 shares during the reporting period[181]. Employee and Community Engagement - The company emphasizes employee rights and satisfaction, focusing on health and safety, and talent development to ensure mutual growth[124]. - The company actively promotes traditional Chinese medicine culture, conducting numerous educational activities for youth in 2022[124].

Financial Performance - The company's revenue for Q1 2022 was CNY 408,730,383.60, representing a 22.19% increase compared to CNY 334,493,742.71 in the same period last year[3] - Net profit attributable to shareholders was CNY 66,855,252.60, up 17.96% from CNY 56,677,913.02 year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 62,208,068.96, reflecting a 10.17% increase from CNY 56,467,371.36 in the previous year[3] - The company reported a significant increase of 1000.00% in non-current assets due within one year, amounting to CNY 1,270,499.99, primarily due to interest from equity disposal[6] - Other income increased by 76.68% to CNY 4,199,465.59, driven by contributions from subsidiaries[6] - Total operating revenue for the current period reached ¥408,730,383.60, an increase from ¥334,493,742.71 in the previous period, representing a growth of approximately 22.2%[24] - Net profit for the current period was ¥74,853,545.20, compared to ¥62,561,935.39 in the previous period, reflecting a growth of approximately 19.0%[27] - The total comprehensive income attributable to the parent company's owners was 66,855,252.60, an increase from 56,677,913.02 in the previous period, representing a growth of approximately 17.4%[31] - Basic and diluted earnings per share were both 0.0821, compared to 0.0696 in the previous period, reflecting an increase of about 18.1%[31] Cash Flow - The net cash flow from operating activities decreased by 27.23% to CNY 49,036,733.84, down from CNY 67,386,448.72 in the same period last year[3] - Cash inflow from operating activities totaled 397,627,479.43, compared to 345,167,492.09 in the previous period, marking an increase of about 15.2%[35] - Cash outflow from operating activities was 348,590,745.59, up from 277,781,043.37 in the previous period, which is an increase of approximately 25.5%[35] - Cash flow from investment activities surged by 1069.23% to ¥152,000,000.00, driven by increased purchases of financial products by subsidiaries[9] - Net cash flow from investing activities was -35,780,083.95, a decline from 3,480,655.07 in the previous period, indicating a significant decrease[35] - Cash inflow from investing activities was 132,045,365.89, compared to 40,343,210.67 in the previous period, representing an increase of about 227%[35] - Cash outflow from financing activities totaled 69,737,246.56, compared to 59,346,535.09 in the previous period, reflecting an increase of approximately 17.5%[38] - The ending cash and cash equivalents balance was 587,566,629.96, down from 600,739,319.32 in the previous period, indicating a decrease of about 2.0%[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,186,456,433.06, a slight decrease of 0.36% from CNY 3,198,096,241.82 at the end of the previous year[3] - Total liabilities decreased to ¥540,606,283.81 from ¥628,539,798.06, a reduction of approximately 14.0%[23] - Shareholders' equity attributable to the parent company increased by 3.03% to CNY 2,303,677,278.16 from CNY 2,235,838,542.50 at the end of the previous year[3] - The company's equity attributable to shareholders increased to ¥2,303,677,278.16 from ¥2,235,838,542.50, showing a growth of about 3.0%[23] Expenses and Impairments - Total operating costs amounted to ¥317,954,488.35, up from ¥275,205,754.61, indicating an increase of about 15.6%[24] - Research and development expenses for the current period were ¥14,784,119.29, slightly up from ¥14,562,216.19, indicating a growth of approximately 1.5%[27] - Credit impairment losses rose by 164.42% to -¥3,105,271.67, primarily due to increased provisions for bad debts[9] - Asset impairment losses increased by 137.64% to -¥5,064,706.23, mainly due to significant inventory write-downs from a subsidiary[9] - The company reported a significant decrease in employee compensation payable, which fell to ¥43,712,493.98 from ¥54,541,707.20, a decline of about 19.8%[23] Taxation - The company recorded a 49.53% increase in taxes payable, totaling CNY 32,123,152.35, attributed to higher VAT and corporate income tax obligations[6] Shareholder Information - The total number of common shareholders at the end of the reporting period was 190,260[9] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 35.20% of the shares, totaling 286,592,160 shares[13]

Financial Performance - The company's operating revenue for 2021 was ¥1,357,868,013.63, representing a 5.97% increase compared to ¥1,281,353,324.60 in 2020[28]. - The net profit attributable to shareholders for 2021 was ¥160,702,159.91, a significant increase of 44.78% from ¥110,993,971.31 in 2020[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥131,160,407.17, up 29.95% from ¥100,929,700.24 in the previous year[28]. - The company's cash flow from operating activities for 2021 was ¥305,570,854.59, a decrease of 6.90% compared to ¥328,218,387.31 in 2020[28]. - The basic earnings per share for 2021 was ¥0.1974, reflecting a 44.83% increase from ¥0.1363 in 2020[28]. - The total assets at the end of 2021 were ¥3,198,096,241.82, which is a 1.33% increase from ¥3,156,027,189.46 at the end of 2020[28]. - The net assets attributable to shareholders at the end of 2021 were ¥2,235,838,542.50, representing a 6.09% increase from ¥2,107,504,709.65 at the end of 2020[28]. - The company achieved consolidated sales revenue of 1.358 billion yuan in 2021, representing a year-on-year growth of 5.97%[67]. - The net profit attributable to the parent company was 161 million yuan, an increase of 44.78% compared to the previous year[67]. Market and Industry Trends - The pharmaceutical industry in China achieved a revenue of CNY 2,928.85 billion in 2021, representing a year-on-year growth of 20.1%[42]. - The aging population in China is projected to exceed 20% of the total population by 2030, significantly increasing the demand for medications tailored to elderly patients[42]. - The centralized procurement of traditional Chinese medicine has led to significant price reductions, prompting the company to enhance its academic brand and optimize market structure to mitigate risks associated with price drops[47]. - The "Internet + Healthcare" initiative is gaining traction, with the company actively pursuing partnerships with online hospitals and pharmacies to explore new growth opportunities[48]. - The long-term prescription management policy introduced by the National Health Commission is expected to facilitate the clinical application of the company's chronic disease medications[46]. Product Development and Innovation - The company is enhancing its product development strategies in response to the challenges and opportunities presented by the centralized procurement policy[47]. - The company is expanding the market for its products through the development of new clinical indications for its existing medications[94]. - The company aims to enhance product competitiveness through ongoing research and development initiatives[94]. - The company has invested 100 million RMB in research and development to innovate new drug formulations and improve existing products[155]. - The company is pursuing the development of innovative drugs, with goals to establish a high-standard R&D center and register new drugs[133]. Corporate Governance and Management - The company has appointed Tianheng Accounting Firm for auditing, ensuring compliance and accuracy in financial reporting[27]. - The company has a dedicated board secretary and securities representative to handle investor relations and communications[22]. - The company has established a comprehensive compliance management system in response to intensified regulatory enforcement, enhancing operational quality and standards[52]. - The company has independent directors who receive remuneration, with one independent director receiving 11.25 thousand yuan in 2021[167]. - The company has established a structured remuneration system that links pay to performance and company results[164]. Risk Management and Compliance - The company emphasizes the importance of risk factors such as raw material procurement, sales price decline, product quality, and environmental safety in its future development outlook[5]. - The company conducted internal control and risk management training twice during the reporting period, enhancing its internal control system[193]. - The company has established a comprehensive internal control system covering major operational areas, with no significant omissions identified[193]. - The company did not identify any significant internal control deficiencies during the reporting period[197]. Shareholder and Investor Relations - The company reported a profit distribution plan of 0.60 CNY per 10 shares (including tax) based on a total share capital of 814,180,908 shares[5]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[188]. - The company plans to implement a three-year shareholder return plan from 2021 to 2023[171]. Employee and Talent Management - The company established a talent development incentive fund of ¥10 million to support talent recruitment and training initiatives[73]. - The employee composition includes 802 production personnel, 235 sales personnel, 416 technical personnel, 69 financial personnel, 151 administrative personnel, and 162 other management personnel[182]. - The company has implemented a competitive salary policy and provides social insurance and housing fund contributions for employees[186]. Strategic Initiatives and Future Outlook - The company is actively participating in the national "Healthy China" strategy, focusing on internal management and external growth through mergers and acquisitions[61]. - The company plans to focus on the sales of key raw materials such as phenobarbital and diethylene glycol, while also exploring new product opportunities[130]. - The company is targeting a significant increase in high-end raw material drug production, aiming to transition from traditional raw materials to high-end generics[129]. - The company is planning to expand its market presence in Southeast Asia, targeting a market share increase of 10% within the next two years[155].

Financial Performance - The company's revenue for Q3 2021 was ¥327,532,499.81, representing a 2.91% increase year-over-year[3] - Net profit attributable to shareholders for Q3 2021 was ¥22,623,737.83, a significant increase of 1,196.26% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥9,979,418.49, reflecting a decrease of 4,231.12% year-over-year[3] - The basic earnings per share for Q3 2021 was ¥0.0278, an increase of 1,212.00% compared to the same period last year[3] - Total operating revenue for the period reached ¥969,008,945.04, an increase from ¥925,636,847.82 in the previous period, representing a growth of approximately 4.1%[23] - The company's net profit attributable to shareholders increased to ¥409,596,732.85 from ¥314,576,800.09, marking a growth of approximately 30.2%[22] - The net profit for the current period is 121,591,358.11, compared to 53,137,228.99 in the previous period, representing an increase of approximately 128.5%[26] - The total profit for the current period is 146,646,371.91, up from 85,339,935.20 in the previous period, indicating a growth of about 72%[26] - Operating profit for the current period is 146,527,593.46, compared to 86,151,101.87 in the previous period, reflecting an increase of approximately 70%[26] Assets and Liabilities - Total assets as of September 30, 2021, were ¥3,130,243,235.16, a decrease of 0.82% from the end of the previous year[3] - The company's total assets decreased to ¥3,130,243,235.16 from ¥3,156,027,189.46, a decline of about 0.8%[19] - Current assets totaled ¥1,439,964,356.29, slightly up from ¥1,420,650,539.13, showing an increase of approximately 1.4%[19] - The total liabilities decreased to ¥574,628,854.64 from ¥669,288,963.02, a reduction of about 14.1%[19] - The company's equity attributable to shareholders rose to ¥2,205,500,779.33 from ¥2,107,504,709.65, an increase of about 4.7%[22] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥228,477,820.16, an increase of 12.55%[3] - Cash flow from operating activities for the current period is 1,060,825,645.53, compared to 942,688,674.74 in the previous period, showing an increase of about 12.5%[30] - Cash flow from investing activities shows a net outflow of -113,339,920.08, compared to -31,278,240.91 in the previous period, indicating a larger investment outflow[33] - Cash flow from financing activities resulted in a net outflow of -179,609,296.52, compared to a net inflow of 90,395,692.50 in the previous period, reflecting a significant change in financing strategy[36] - The cash and cash equivalents at the end of the period amount to 514,494,174.68, down from 559,639,859.29 in the previous period, a decrease of approximately 8%[36] Investments and Expenses - R&D expenses increased by 49.43% to ¥53,347,000.10 compared to ¥35,700,813.05 in the same period last year, attributed to higher investment in R&D and capitalization of project adjustments[9] - Financial expenses decreased by 104.83% to -¥704,720.56, primarily due to increased deposit income and reduced interest payments on bank loans[9] - Investment income dropped by 72.70% to ¥3,555,661.44 from ¥13,026,354.80, mainly due to the previous year's higher profits from associated companies[9] - Fair value changes in investment increased by 742.75% to ¥30,918,592.43, driven by price fluctuations in Kadmon Company stock[9] - Cash recovered from investments rose by 673.66% to ¥179,576,646.56, attributed to an increase in financial products purchased[9] - Dividend distribution increased by 264.00% to ¥67,377,296.52, indicating a higher dividend payout during the reporting period[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,577, with the largest shareholder holding 34.29% of the shares[9] - The top ten shareholders collectively hold significant stakes, with the largest shareholder, Nantong Industrial Holding Group Co., Ltd., owning 286,592,160 shares[12] Audit and Reporting - The third quarter report of the company was not audited[37] - The company implemented new leasing standards starting in 2021, but did not apply retrospective adjustments to prior comparative data[37] - The financial statements for the first year of the new leasing standards were adjusted at the beginning of the year[37] - The company’s board of directors provided the third quarter report without an audit[37] - There were no applicable adjustments for the new leasing standards in the previous periods[37] - The company did not disclose any specific financial performance metrics or user data in the provided content[37] - Future outlook and performance guidance were not mentioned in the content[37] - There were no new products, technologies, market expansions, or mergers discussed in the content[37] - The company did not provide any strategic initiatives or changes in strategy in the content[37] - The content primarily focused on the audit status and leasing standard adjustments without detailed financial insights[37]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 641,476,445.23, representing a 5.62% increase compared to CNY 607,370,691.95 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was CNY 105,777,610.05, a 1.99% increase from CNY 103,714,325.87 year-on-year[27]. - The net profit after deducting non-recurring gains and losses was CNY 103,228,338.93, up 3.41% from CNY 99,819,845.57 in the previous year[27]. - The net cash flow from operating activities increased by 49.46% to CNY 184,063,744.31 from CNY 123,153,411.67 in the same period last year[27]. - Total assets at the end of the reporting period were CNY 3,199,059,649.23, a 1.36% increase from CNY 3,156,027,189.46 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were CNY 2,182,173,155.73, reflecting a 3.54% increase from CNY 2,107,504,709.65 at the end of the previous year[27]. - Basic earnings per share for the reporting period were CNY 0.1299, a 1.96% increase from CNY 0.1274 in the same period last year[27]. - The weighted average return on net assets was 4.90%, down 0.55% from 5.45% in the previous year[27]. Revenue Breakdown - Revenue from the pharmaceutical industry accounted for 91.90% of total operating revenue, with a year-on-year growth of 5.51%[55]. - Domestic revenue was ¥580,613,313.24, accounting for 90.51% of total revenue, with a year-on-year increase of 7.67%[58]. - International revenue decreased by 10.65% to ¥60,863,131.99, representing 9.49% of total revenue[55]. - Sales revenue for Wang's Baochi Pill reached ¥68 million, a 56.6% increase compared to the same period last year[40]. - Sales revenue for Jidesheng Snake Medicine Tablets was ¥43 million, reflecting a 6% increase year-on-year[40]. Costs and Expenses - The operating costs increased by 4.44%, amounting to ¥328,219,562.95, up from ¥314,256,143.15 in the previous year[51]. - Sales expenses rose by 10.54% to ¥87,134,695.48, compared to ¥78,827,030.98 in the same period last year[51]. - Management expenses saw a significant increase of 19.04%, totaling ¥63,188,830.15, up from ¥53,082,413.60[51]. - The financial expenses decreased by 91.59%, amounting to ¥688,822.56, primarily due to reduced interest payments on bank loans during the reporting period[51]. - The income tax expense decreased by 27.23%, totaling ¥18,824,500.82, down from ¥25,869,543.93 in the previous year[51]. Research and Development - The company is advancing the construction of a new project for the annual production of 6,000 tons of Dioxane, which has already commenced[40]. - The company has filed for two invention patents and eight utility model patents during the reporting period[40]. - The company invests heavily in drug research and development, facing risks of increased costs and potential failures in the approval process[85]. Quality Control and Compliance - The market inspection pass rate for the company's products was 100%, with no major quality incidents reported[40]. - The company has implemented a strict quality management system, adhering to GMP and ISO standards, with zero incidents of major quality issues[40]. - The company emphasizes quality control, having established a comprehensive quality assurance system that meets Chinese pharmacopoeia and GMP production standards[48]. - The company reported no instances of exceeding pollutant discharge standards in its environmental compliance[104]. Environmental Management - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including the preparation of emergency plans and regular employee drills[115]. - The company has installed online monitoring systems for wastewater, conducting self-tests twice daily and hiring qualified third parties for quarterly monitoring[118]. - The company conducts environmental monitoring in strict accordance with industry standards, including annual monitoring of organized and unorganized waste gas, wastewater, and quarterly noise monitoring[122]. - The company has implemented a comprehensive environmental risk prevention strategy, including the establishment of an emergency response center[115]. Community Engagement and Social Responsibility - The company invested CNY 10.793 million in local herbal medicine procurement, creating 57 jobs in Longxi County[127]. - The company trained over 300 individuals in organic planting techniques for traditional Chinese medicinal herbs during the reporting period[127]. - The company donated medicines to support pandemic relief efforts, including Wang's Baoshisan and Zheng Chaihu Granules[127]. - The company aims to ensure that impoverished households do not fall back into poverty by increasing income through high-value organic medicinal herb cultivation[127]. Risks and Challenges - The company faces risks related to raw material procurement, sales price declines, product quality, and environmental safety[6]. - The company anticipates potential declines in product sales prices due to national medical reform and pricing policies[84]. - The company faces risks related to regulatory changes, particularly with the new Drug Administration Law and the impact on traditional Chinese medicine production[82]. - The company has identified risks related to talent shortages as it expands its operations, which may impact management and operational capabilities[90]. Shareholder Information - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 286,592,160 shares, accounting for 34.29% of the total shares[172]. - The second-largest shareholder, Zan Shengda, holds 110,422,757 shares, representing 13.21% of the total[172]. - The total number of shareholders holding more than 5% of the shares is 10, with a total of 36,921 ordinary shareholders[169]. - The company has not conducted any repurchase transactions during the reporting period[176]. Governance and Management - The company has a relatively complete governance structure and operational system to meet current management and development needs[90]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[180]. - The financial report for the first half of 2021 was not audited[191].

Financial Performance - The company's operating revenue for Q1 2021 was ¥334,493,742.71, representing a 9.83% increase compared to ¥304,542,238.53 in the same period last year[9] - The net profit attributable to shareholders for Q1 2021 was ¥56,677,913.02, up 5.07% from ¥53,945,183.55 in the previous year[9] - The basic earnings per share for Q1 2021 was ¥0.0696, a 4.98% increase from ¥0.0663 in the same period last year[9] - The company reported a decrease of 1.37% in net profit after deducting non-recurring gains and losses, totaling ¥56,467,371.36 compared to ¥57,253,335.34 in the previous year[9] - The company reported a total comprehensive income of ¥62,561,935.39, compared to ¥54,338,530.47 from the previous period[63] - Net profit for the current period was ¥62,561,935.39, representing a 15.5% increase from ¥54,338,530.47 in the previous period[61] Cash Flow and Liquidity - The net cash flow from operating activities increased by 39.81% to ¥67,386,448.72, compared to ¥48,197,106.08 in the same period last year[9] - The company's cash and cash equivalents increased to ¥606,292,455.51 as of March 31, 2021, up from ¥581,318,648.60 at the end of 2020, representing a growth of 4.67%[39] - Cash flow from operating activities increased to 67,386,448.72 from 48,197,106.08, representing a growth of approximately 39.5%[75] - Cash and cash equivalents at the end of the period reached 600,739,319.32, compared to 295,650,387.20 at the end of the previous period, marking an increase of approximately 102.6%[78] - The net increase in cash and cash equivalents was -$8,199,298.78, with a beginning balance of $167,317,758.43, resulting in an ending balance of $159,118,459.65[82] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,160,957,880.85, a slight increase of 0.16% from ¥3,156,027,189.46 at the end of the previous year[9] - The net assets attributable to shareholders increased by 2.72% to ¥2,164,817,838.44 from ¥2,107,504,709.65 at the end of the previous year[9] - Current liabilities totaled approximately $530.74 million, a slight increase from $528.48 million[45] - Total liabilities decreased to approximately $610.72 million from $669.29 million[45] - Total non-current assets decreased slightly to approximately $1.73 billion from $1.74 billion[42] Expenses and Investments - Research and development expenses rose to ¥14,562,216.19 in Q1 2021, a 47.10% increase compared to ¥9,899,701.65 in Q1 2020, due to increased investment in technological innovation[22] - The company reported a significant increase in other income, which reached ¥2,376,892.74 in Q1 2021, up 438.72% from ¥441,208.68 in Q1 2020, primarily due to increased government subsidies[22] - The company reported a decrease in investment income, which fell by 56.24% to ¥1,168,845.34 from ¥2,670,961.73, primarily due to reduced profits from an associated company[22] - The company incurred a credit impairment loss of 225,720.48, down from 689,114.10, reflecting a decrease of approximately 67.2%[72] Shareholder Information - The top shareholder, Nantong Industrial Holdings Group, held 34.29% of the shares, with a total of 286,592,160 shares[14] - The company reported an increase in undistributed profits to approximately $371.25 million from $314.58 million[48] - Total equity attributable to shareholders increased to approximately $2.16 billion from $2.11 billion[48] Other Information - The company did not report any non-recurring gains or losses that were classified as regular gains or losses during the reporting period[12] - The first quarter report for 2021 was not audited[86]

Financial Performance - The company's revenue for Q1 2021 was ¥334,493,742.71, representing a 9.83% increase compared to ¥304,542,238.53 in the same period last year[9] - Net profit attributable to shareholders was ¥56,677,913.02, up 5.07% from ¥53,945,183.55 year-on-year[9] - Basic earnings per share rose to ¥0.0696, a 4.98% increase from ¥0.0663 in the same period last year[9] - The company reported a decrease of 1.37% in net profit after deducting non-recurring gains and losses, totaling ¥56,467,371.36 compared to ¥57,253,335.34 last year[9] - Net profit for the current period was ¥62,561,935.39, up 15.5% from ¥54,338,530.47 in the previous period[61] - The total comprehensive income attributable to the parent company was ¥56,677,913.02, compared to ¥53,945,183.55, an increase of 5.4%[64] Cash Flow - The net cash flow from operating activities increased by 39.81% to ¥67,386,448.72, compared to ¥48,197,106.08 in the previous year[9] - Cash received from other operating activities increased significantly to 33,060,451.62 from 13,321,216.32, a rise of 148.18% due to an increase in other cash receipts[22] - The company's cash flow from investment recovery increased to 36,124,715.80 from 23,211,200.00, a rise of 55.63% due to the maturity of financial products held by subsidiaries[22] - The company's cash and cash equivalents increased to 606,292,455.51 from 581,318,648.60, reflecting a positive cash flow position[39] - The cash and cash equivalents at the end of the period increased to 600,739,319.32 from 295,650,387.20, indicating a significant rise of approximately 102.3%[78] - The company’s cash flow from financing activities resulted in a net outflow of -49,608,535.09, compared to -69,261,726.12 in the previous period, showing an improvement of approximately 28.4%[78] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,160,957,880.85, a slight increase of 0.16% from ¥3,156,027,189.46 at the end of the previous year[9] - The company's total liabilities decreased to ¥610,717,479.17 from ¥669,288,963.02, a reduction of approximately 8.73%[45] - Current liabilities totaled ¥530,738,103.66, a marginal increase from ¥528,484,288.86, representing a growth of about 0.24%[45] - The company's long-term borrowings decreased from 60,000,000.00 to 120,000,000.00, a reduction of 50.00% as a subsidiary reclassified long-term borrowings to current liabilities[22] - The total current assets amounted to ¥451,213,691.56, slightly down from ¥458,006,194.54, a decrease of about 1.73%[49] Shareholder Information - The top shareholder, Nantong Industrial Holding Group Co., Ltd., holds 34.29% of the shares, with a total of 286,592,160 shares[14] - Net assets attributable to shareholders increased by 2.72% to ¥2,164,817,838.44 from ¥2,107,504,709.65 at the end of the previous year[9] - The total equity attributable to shareholders increased to ¥2,164,817,838.44 from ¥2,107,504,709.65, reflecting a growth of about 2.72%[48] Expenses and Investments - Total operating costs increased to ¥275,205,754.61 from ¥238,064,393.99, reflecting a rise of 15.6%[58] - Research and development expenses increased by 14,562,216.19 to 9,899,701.65, a rise of 47.10% due to increased investment in technological innovation[22] - The company reported a decrease in financial expenses from 595,347.23 to 3,789,040.81, a decline of 84.29% due to reduced interest payments on bank loans[22] - Investment income decreased to 1,168,845.34 from 2,670,961.73, a drop of 56.24% primarily due to reduced profits from an associated company[22] - The company reported an investment income of ¥940,187.81, down from ¥2,670,961.73, a decrease of 64.8%[65] Other Information - The company did not engage in any repurchase transactions during the reporting period[19] - The first quarter report for 2021 was not audited[86] - The company did not require adjustments to the beginning balance of the balance sheet due to the adoption of the new leasing standards, as it only has short-term leasing operations[85]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2020, representing a year-on-year growth of 15%[18] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[18] - The company's operating revenue for 2020 was ¥1,281,353,324.60, representing a 10.71% increase compared to ¥1,157,389,428.34 in 2019[26] - The net profit attributable to shareholders for 2020 was ¥110,993,971.31, a significant turnaround from a loss of ¥393,617,953.72 in 2019, marking a 128.20% increase[26] - The net cash flow from operating activities increased by 15.01% to ¥328,218,387.31 in 2020, up from ¥285,382,129.55 in 2019[26] - The total assets at the end of 2020 were ¥3,156,027,189.46, a 7.30% increase from ¥2,941,338,590.70 at the end of 2019[26] - The net assets attributable to shareholders increased by 13.92% to ¥2,107,504,709.65 at the end of 2020, compared to ¥1,849,906,867.35 at the end of 2019[26] - The company reported a basic earnings per share of ¥0.1363 in 2020, a recovery from a loss of ¥0.4835 in 2019, representing a 128.19% increase[26] - The company’s weighted average return on equity improved to 5.64% in 2020, compared to -19.08% in 2019, an increase of 24.72%[26] - The company achieved a consolidated sales revenue of 1.281 billion RMB in 2020, representing a year-on-year growth of 10.71%[55] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of 0.41 RMB per 10 shares, based on a total of 814,180,908 shares[6] - The company reported a cash dividend of 0.41 yuan per 10 shares for the year 2020, totaling 33,381,417.23 yuan, which represents 30.07% of the net profit attributable to ordinary shareholders[137] - The company did not distribute cash dividends or bonus shares for the year 2019, and the profit distribution plan for 2020 was approved with a base of 814,180,908 shares[137] Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[18] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[18] - The company is actively expanding into emerging markets and increasing self-export efforts for raw materials[60] - The company aims to become a leading modern pharmaceutical enterprise in China, focusing on traditional Chinese medicine and high-end raw materials, with a dual-driven strategy[110] - The company is focusing on e-commerce development and strategic partnerships with major commercial companies to expand sales channels[114] Research and Development - New product development includes a pipeline of 10 new drugs expected to launch in 2021, with projected sales of 300 million RMB[18] - The company has invested 50 million RMB in R&D for new technologies aimed at improving product quality and safety[18] - R&D investment increased by 9.73% to ¥54,821,199.78 in 2020, with the number of R&D personnel rising by 34% to 335[82] - The proportion of R&D investment to operating revenue slightly decreased to 4.28% from 4.32% in 2019[82] - The company completed a bioequivalence study for a generic drug, demonstrating its commitment to R&D in chemical pharmaceuticals[79] Product and Sales Performance - User data showed an increase in active users by 25% year-on-year, reaching 5 million active users by the end of 2020[18] - The pharmaceutical manufacturing segment generated ¥1,172,768,363.27, accounting for 91.53% of total revenue, with a growth of 12.81% from ¥1,039,593,562.20 in 2019[65] - The gross profit margin for the pharmaceutical manufacturing sector improved to 51.38%, up by 2.26% from the previous year[68] - The sales volume of traditional Chinese medicine preparations increased by 6.67% to 21,114,024 bags/bottles in 2020 compared to 19,794,248 in 2019[69] - The sales volume of chemical pharmaceutical intermediates surged by 34.35%, primarily due to increased sales from subsidiaries Nantong Senxuan and Nantong Dongli[69] Risk Management - The company identified risks related to raw material procurement and pricing fluctuations, with strategies in place to mitigate these risks[6] - The company faces risks related to raw material procurement due to the scarcity of wild resources and price volatility, which could significantly impact profitability[125] - The company anticipates potential declines in product sales prices due to national healthcare reforms and competitive market strategies, which may adversely affect profit levels[126] - The company acknowledges the risk of insufficient management and professional talent as it expands its operations and business scope[129] Corporate Social Responsibility - The company was recognized as an excellent corporate social responsibility performer in 2020 by Health News[60] - The company donated CNY 1 million to the China Red Cross Foundation to support medical teams during the COVID-19 pandemic[192] - The company provided 300,000 tablets of chloroquine phosphate and 24,000 bottles of a traditional medicine to Iran to assist in their COVID-19 response, valued at CNY 834,000[189] - The company certified 50,000 acres of organic Chinese medicinal herb planting bases in several national-level poverty-stricken counties, with a planting scale of 15,400 acres for high-value herbs like Codonopsis and Angelica[189] Environmental Compliance - The company has passed ISO 14001 certification, emphasizing its commitment to environmental protection and safety production[196] - The company has established a wastewater treatment facility with a daily capacity of 1000 tons, ensuring effective operation through a 24-hour monitoring system[200] - The company has implemented a comprehensive pollution control strategy, including advanced wastewater and waste gas treatment systems, ensuring compliance with environmental standards[200] - Jinghua Pharmaceutical Group Nantong Co., Ltd. reported a total COD emission of 10.216 tons, well below the approved limit of 117.115 tons per year[197] Governance and Compliance - The company has a well-established governance structure and operational system, but effective management of subsidiaries is crucial for sustainable development[129] - The company has not faced any bankruptcy reorganization matters during the reporting period[150] - The company has no penalties or rectification situations during the reporting period[152] - The company has not reported any major related party transactions during the reporting period[156]